Skip to main content

Table 1 Patient characteristics

From: Severe intestinal dysbiosis is prevalent in primary Sjögren’s syndrome and is associated with systemic disease activity

  pSS patients (N = 42)
Age (years) 62 (51; 68)
Sex (males/females) 2/40
Disease duration (years) 16 (7; 23)
Current/prior/never smokers (%) 20/41/39
Anti-SS-A antibody seropositives (%) 76
Anti-SS-B antibody seropositives (%) 48
ANA seropositives (%) 79
RF seropositives (%) 52
IgG (g/L) 13.1 (10.0; 17.1)
Complement component 3 (g/L) 1.00 (0.89; 1.15)
Complement component 4 (g/L) 0.16 (0.12; 0.21)
Lip biopsy—focus score ≥ 1 (N positives/N studied (%)) 28/33 (85)
ESSDAI total score 6 (1; 12)
ESSPRI total score 6 (5; 8)
Fecal calprotectin (μg/g) 38 (20; 123)
Irritable bowel syndrome-like symptoms (%) 42
Using proton pump inhibitors (%) 36
Using NSAIDs (%) 38
Using glucocorticoids (%) 36
  > 5 mg prednisolone daily 7
 5 mg prednisolone daily 24
  < 5 mg prednisolone daily 5
Using anti-malarials (%) 29
Using other DMARDs (%) 2
  1. Demographic and clinical characteristics of the patients with primary Sjögren’s syndrome (pSS). Results presented as median (interquartile range) or percentage of subjects
  2. DMARD disease-modifying anti-rheumatic drug, ESSDAI EULAR Sjögren’s Syndrome Disease Activity Index, ESSPRI EULAR Sjögren’s Syndrome Patient Reported Index, EULAR European League Against Rheumatism, NSAID nonsteroidal anti-inflammatory drug, ANA antinuclear antibodies, RF rheumatoid factor